Active broad-market exchange-traded funds in Monday’s pre-market session:
SPDR Select Sector Fund – Financial ( XLF ): -0.2%
iPath S&P 500 VIX Short Term Futures ETN ( VXX ): -1.8%
iShares MSCI Emerging Index Fund ( EEM ): -0.3%
SPDR S&P 500 ( SPY ): +0.1%
VanEck Vectors Gold Miners ETF ( GDX ): +1.1%
Broad Market Indicators
Broad-market exchange-traded funds, including SPY, IWM and IVV edged lower. Actively traded PowerShares QQQ (QQQ) was up 0.2%.
U.S. stock futures were pointing higher, after softer-than-expected Empire State index data, but market direction is expected to be more definite when earnings season begin in earnest.
The New York Fed’s Empire State manufacturing index declined to a seasonally adjusted reading of 9.8 from 19.8 in June. Expectations were for a reading of 15.
Netflix (NFLX) will be reporting its financial results in the after hours session.
Power Play: Health Care
Health care funds Health Care SPDR (XLV), Vanguard Health Care ETF (VHT) and iShares Dow Jones US Healthcare (IYH), were inactive. Biotechnology fund iShares NASDAQ Biotechnology Index (IBB) was up 0.3%.
Repros Therapeutics (RPRX) plunged 46.5% after the company said its clinical development program for Proellex will remain on partial clinical hold, and based upon the US Food and Drug Administration’s review of all the existing liver function safety data, the regulator has indicated the company will be required to compile a large pre-approval safety data base to support future development. Proellex is the company’s oral delivery mechanism for telapristone acetate. As a result, Repros said it is assessing increasing its focus on its uterine fibroid and endometriosis development program utilizing a vaginal drug delivery program for telapristone acetate, a selective progesterone modulator. The company also said on Aug 2, it will be granted a European patent relating to the use of selective progesterone modulators, in particular Telapristone Acetate…